Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Stem Cells ; 22(5): 770-8, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15342941

RESUMEN

Murine embryonic stem (mES) cells remain undifferentiated in the presence of leukemia inhibitory factor (LIF), and activation of signal transducer and activator of transcription 3 (STAT3) via LIF receptor (LIFR) signaling appears sufficient for maintenance of mES cell pluripotency. Anecdotal and contradictory accounts exist for the action of LIF in the culture of human embryonic stem cells, and the nature of LIF signaling and whether the LIF-STAT3 pathway is conserved in human embryonic stem cells (hESCs) has not been systematically explored. In this study, we show that the LIFRbeta and the signaling subunit gp130 are expressed in hESCs and that human LIF can induce STAT3 phosphorylation and nuclear translocation in hESCs. Nevertheless, despite the functional activation of the LIF-STAT3 signaling pathway, human LIF is unable to maintain the pluripotent state of hESCs. Feeder-free culture conditions that maintain hESCs in an undifferentiated state do not show activation of STAT3, suggesting that distinct signaling mechanisms govern the self-renewal of hESCs.


Asunto(s)
División Celular/genética , Proteínas de Unión al ADN/metabolismo , Células Madre Pluripotentes/metabolismo , Proteínas/metabolismo , Trasplante de Células Madre/métodos , Transactivadores/metabolismo , Transporte Activo de Núcleo Celular/efectos de los fármacos , Transporte Activo de Núcleo Celular/genética , Animales , Antígenos CD/genética , Antígenos CD/metabolismo , Técnicas de Cultivo de Célula/métodos , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/genética , División Celular/efectos de los fármacos , Línea Celular , Núcleo Celular/efectos de los fármacos , Núcleo Celular/genética , Núcleo Celular/metabolismo , Proliferación Celular/efectos de los fármacos , Medios de Cultivo Condicionados/farmacología , Receptor gp130 de Citocinas , Proteínas de Unión al ADN/genética , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/genética , Humanos , Interleucina-6 , Factor Inhibidor de Leucemia , Subunidad alfa del Receptor del Factor Inhibidor de Leucemia , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/metabolismo , Ratones , Fosforilación/efectos de los fármacos , Células Madre Pluripotentes/efectos de los fármacos , Células Madre Pluripotentes/inmunología , Subunidades de Proteína/genética , Subunidades de Proteína/metabolismo , Proteínas/genética , Proteínas/farmacología , Receptores de Citocinas/genética , Receptores de Citocinas/metabolismo , Receptores OSM-LIF , Factor de Transcripción STAT3 , Transducción de Señal/efectos de los fármacos , Transducción de Señal/genética , Transactivadores/genética
2.
Blood ; 104(1): 11-8, 2004 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-14976060

RESUMEN

The alternatively spliced and highly conserved EIIIA domain of fibronectin (FN) is included in most FN of the extracellular matrix in embryos. In adults, both extracellular matrix and plasma FN essentially lack EIIIA. In diverse inflammatory situations however, EIIIA is specifically included by regulated RNA splicing. In atherosclerotic lesions, FN, including the EIIIA domain (EIIIA-FN), is abundant, whereas FN in the flanking vessel wall lacks EIIIA. Lesional EIIIA-FN is localized with endothelial cells and macrophage foam cells. To directly test the function of EIIIA-FN, we generated EIIIA-null (EIIIA(-/-)) mice that lack the EIIIA exon and crossed them with apolipoprotein E (ApoE)-null (ApoE(-/-)) mice that develop arterial wall lesions. Compared with ApoE(-/-) controls, EIIIA(-/-)ApoE(-/-) mice had significantly smaller lesions throughout the aortic tree. EIIIA-FN was increased in ApoE(-/-) plasma, and total plasma cholesterol was reduced in EIIIA(-/-)ApoE(-/-) mice, specifically in large lipoprotein particles, suggesting a functional role for plasma EIIIA-FN. To assess a role for macrophage EIIIA-FN in the vessel wall, we conducted in vitro foam cell assays. EIIIA(-/-)ApoE(-/-) macrophages accumulated significantly less intracellular lipid than control ApoE(-/-) cells. These results provide genetic evidence that suggests roles for EIIIA-FN in plasma lipoprotein metabolism and in foam cell formation.


Asunto(s)
Arteriosclerosis/genética , Arteriosclerosis/metabolismo , Fibronectinas/fisiología , Empalme Alternativo/genética , Animales , Animales Recién Nacidos , Aorta/patología , Aorta/ultraestructura , Apolipoproteínas E/deficiencia , Apolipoproteínas E/genética , Arteriosclerosis/prevención & control , Colesterol/sangre , Grasas de la Dieta , Exones/genética , Matriz Extracelular/metabolismo , Femenino , Fibroblastos/metabolismo , Fibronectinas/sangre , Fibronectinas/deficiencia , Fibronectinas/genética , Células Espumosas/metabolismo , Células Espumosas/patología , Células Espumosas/ultraestructura , Eliminación de Gen , Humanos , Lipoproteínas VLDL/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Noqueados , Isoformas de Proteínas , Estructura Terciaria de Proteína
3.
Biol Proced Online ; 5: 204-210, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-14615817

RESUMEN

The discovery of oncogenes and signal transduction pathways important for mitogenesis has triggered the development of target-specific small molecule anti-cancer compounds. As exemplified by imatinib (Gleevec), a specific inhibitor of the Chronic Myeloid Leukemia (CML)-associated Bcr-Abl kinase, these agents promise impressive activity in clinical trials, with low levels of clinical toxicity. However, such therapy is susceptible to the emergence of drug resistance due to amino acid substitutions in the target protein. Defining the spectrum of such mutations is important for patient monitoring and the design of next-generation inhibitors. Using imatinib and BCR/ABL as a paradigm for a drug-target pair, we recently reported a retroviral vector-based screening strategy to identify the spectrum of resistance-conferring mutations. Here we provide a detailed methodology for the screen, which can be generally applied to any drug-target pair.

4.
Mol Cell Biol ; 22(3): 901-15, 2002 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11784865

RESUMEN

The integrin family of cell adhesion receptors are important for a diverse set of biological responses during development. Although many integrins have been shown to engage a similar set of cytoplasmic effector proteins in vitro, the importance of these proteins in the biological events mediated by different integrin receptors and ligands is uncertain. We have examined the role of one of the best-characterized integrin effectors, the focal adhesion protein paxillin, by disruption of the paxillin gene in mice. Paxillin was found to be critically involved in regulating the development of mesodermally derived structures such as heart and somites. The phenotype of the paxillin(-/-) mice closely resembles that of fibronectin(-/-) mice, suggesting that paxillin is a critical transducer of signals from fibronectin receptors during early development. Paxillin was also found to play a critical role in fibronectin receptor biology ex vivo since cultured paxillin-null fibroblasts display abnormal focal adhesions, reduced cell migration, inefficient localization of focal adhesion kinase (FAK), and reduced fibronectin-induced phosphorylation of FAK, Cas, and mitogen-activated protein kinase. In addition, we found that paxillin-null fibroblasts show some defects in the cortical cytoskeleton and cell spreading on fibronectin, raising the possibility that paxillin could play a role in structures distinct from focal adhesions. Thus, paxillin and fibronectin regulate some common embryonic developmental events, possibly due to paxillin modulation of fibronectin-regulated focal adhesion dynamics and organization of the membrane cytoskeletal structures that regulate cell migration and spreading.


Asunto(s)
Proteínas del Citoesqueleto/fisiología , Desarrollo Embrionario y Fetal/fisiología , Fibronectinas/fisiología , Fosfoproteínas/fisiología , Animales , Movimiento Celular/fisiología , Células Cultivadas , Proteínas del Citoesqueleto/deficiencia , Proteínas del Citoesqueleto/genética , Desarrollo Embrionario y Fetal/genética , Quinasa 1 de Adhesión Focal , Proteína-Tirosina Quinasas de Adhesión Focal , Adhesiones Focales/fisiología , Regulación del Desarrollo de la Expresión Génica , Marcación de Gen , Mesodermo/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Paxillin , Fenotipo , Fosfoproteínas/deficiencia , Fosfoproteínas/genética , Fosforilación , Proteínas Tirosina Quinasas/metabolismo , Receptores de Fibronectina/fisiología , Transducción de Señal , Tirosina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA